DRRX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: ALKS MDGL ARWR ADMA CORT ACET TBPH BCRX ADAP SCYX

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	12.59%	Shs Outstand	31.04M	Perf Week	-1.55%
Market Cap	59.31M	Forward P/E	-	EPS next Y	-0.70	Insider Trans	5.68%	Shs Float	27.14M	Perf Month	2.14%
Enterprise Value	54.56M	PEG	-	EPS next Q	-0.18	Inst Own	23.50%	Short Float	1.27%	Perf Quarter	232.17%
Income	-14.50M	P/S	18.83	EPS this Y	-164.00%	Inst Trans	5.54%	Short Ratio	0.29	Perf Half Y	133.38%
Sales	3.15M	P/B	17.02	EPS next Y	-6.06%	ROA	-58.71%	Short Interest	0.34M	Perf YTD	154.67%
Book/sh	0.11	P/C	9.12	EPS next 5Y	-	ROE	-291.74%	52W High	2.64 -27.65%	Perf Year	21.66%
Cash/sh	0.21	P/FCF	-	EPS past 3/5Y	26.42% 11.09%	ROIC	-350.62%	52W Low	0.48 297.83%	Perf 3Y	-73.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-47.43% -39.51%	Gross Margin	79.96%	Volatility	2.05% 1.80%	Perf 5Y	-89.33%
Dividend TTM	-	EV/Sales	17.32	EPS Y/Y TTM	11.60%	Oper. Margin	-455.02%	ATR (14)	0.05	Perf 10Y	-90.73%
Dividend Ex-Date	-	Quick Ratio	0.95	Sales Y/Y TTM	-62.57%	Profit Margin	-460.55%	RSI (14)	67.28	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.98	EPS Q/Q	38.76%	SMA20	-0.44%	Beta	0.93	Target Price	2.50
Payout	-	Debt/Eq	0.50	Sales Q/Q	-79.41%	SMA50	35.96%	Rel Volume	0.00	Prev Close	1.91
Employees	31	LT Debt/Eq	0.19	Earnings	Aug 12 AMC	SMA200	108.89%	Avg Volume	1.18M	Price	1.91
IPO	Sep 28, 2000	Option/Short	Yes / No	EPS/Sales Surpr.	46.15% 39.69%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-20	Initiated	Chardan Capital Markets	Buy	$7
Oct-12-20	Initiated	ROTH Capital	Buy
Jul-31-20	Initiated	Oppenheimer	Outperform	$7
Jan-31-20	Initiated	B. Riley FBR	Buy	$5
Nov-18-19	Resumed	Cantor Fitzgerald	Overweight
Sep-06-19	Initiated	Cantor Fitzgerald	Overweight	$5
Mar-06-18	Upgrade	H.C. Wainwright	Neutral → Buy	$3.50
Oct-20-17	Reiterated	Laidlaw	Buy	$3 → $2
Oct-20-17	Downgrade	Stifel	Buy → Hold	$3 → $0.90
Oct-20-17	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-12-17	Upgrade	Stifel	Hold → Buy	$1.25 → $3
Feb-28-17	Resumed	H.C. Wainwright	Buy	$3
Apr-25-16	Initiated	Rodman & Renshaw	Buy	$4
May-01-15	Reiterated	Stifel	Buy	$1.50 → $2.50
May-01-15	Reiterated	Cantor Fitzgerald	Buy	$2.50 → $3
Mar-25-13	Initiated	Stifel	Buy	$3
Nov-01-12	Downgrade	C.K. Cooper	Buy → Hold	$3
Aug-17-12	Initiated	C.K. Cooper	Buy	$3
Jun-23-09	Initiated	Caris & Company	Buy	$5
Mar-26-09	Initiated	Wedbush Morgan	Hold

Show Previous Ratings

Sep-11-25 08:35AM	Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio (PR Newswire)
Aug-26-25 08:00AM	Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025 (ACCESSWIRE)
Aug-12-25 06:05PM	Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:02PM	Durect: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health (PR Newswire)
11:52PM	Loading…
Aug-08-25 11:52PM	Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment (Insider Monkey)
Jul-31-25 10:48AM	Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat (Zacks)
Jul-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +240.15%
07:00AM	Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease (PR Newswire)
May-14-25 06:56PM	Durect: Q1 Earnings Snapshot (Associated Press Finance)
May-13-25 04:05PM	DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
May-07-25 06:25PM	Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates (Zacks) +12.71%
Mar-27-25 07:20AM	Q4 2024 DURECT Corp Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges (GuruFocus.com)
Mar-26-25 08:04PM	DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:20PM	Loading…
05:20PM	Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:22PM	Durect: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Mar-25-25 09:04AM	What To Expect From Durect Corp (DRRX) Q4 2024 Earnings (GuruFocus.com)
Mar-20-25 08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
Mar-19-25 04:30PM	DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update (PR Newswire)
Feb-04-25 07:30AM	DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-28-25 10:09AM	DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence (PR Newswire)
Jan-16-25 12:00PM	Durect (DRRX) Upgraded to Strong Buy: Here's Why (Zacks)
Dec-11-24 12:00PM	Durect (DRRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-25-24 06:00AM	DURECT Corporation Announces Sale of ALZET Product Line to Lafayette Instrument Co. for $17.5 Million (PR Newswire)
Nov-14-24 07:49AM	Q3 2024 DURECT Corp Earnings Call (Thomson Reuters StreetEvents) -7.44%
02:15AM	Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... (GuruFocus.com)
Nov-13-24 05:10PM	Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.20%
04:08PM	Durect: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-06-24 04:45PM	DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update (PR Newswire) -8.16%
Oct-17-24 08:30AM	DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 (PR Newswire)
Oct-09-24 06:19PM	Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... (GuruFocus.com)
Sep-25-24 08:00AM	DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis (PR Newswire)
Sep-04-24 04:30PM	DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +8.90%
Aug-13-24 05:15PM	Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.67%
04:08PM	Durect: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update (PR Newswire)
Aug-07-24 04:30PM	DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update (PR Newswire) +12.21%
Jun-19-24 09:40AM	Are Medical Stocks Lagging DURECT (DRRX) This Year? (Zacks)
May-21-24 11:17AM	Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment (MT Newswires) +24.04%
08:00AM	DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis (PR Newswire)
May-14-24 01:21PM	Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says (MT Newswires) -14.02%
11:44AM	Q1 2024 DURECT Corp Earnings Call (Thomson Reuters StreetEvents)
08:20AM	DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:03AM	Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ... (GuruFocus.com)
May-13-24 08:54PM	DRRX Stock Earnings: Durect Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:20PM	Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Durect: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update (PR Newswire)
May-07-24 04:30PM	DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update (PR Newswire) -15.00%
Apr-30-24 07:00AM	DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis (PR Newswire)
Apr-01-24 02:11PM	DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.26%
Mar-27-24 08:53PM	DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.51% -9.70%
05:10PM	Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:19PM	Durect: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Mar-20-24 04:30PM	DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update (PR Newswire) +8.47%
Mar-04-24 07:00AM	DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET Product Line in U.S. and Canada (PR Newswire)
Feb-07-24 06:48PM	DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire) -6.69% +7.08%
Nov-14-23 08:05AM	Q3 2023 DURECT Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 04:40PM	Durect: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update (PR Newswire)
Nov-09-23 04:30PM	DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update (PR Newswire) +8.29% -7.06%
Nov-08-23 08:40AM	Why Is Durect (DRRX) Stock Down 64% Today? (InvestorPlace) -79.57%
07:59AM	Durect fails alcohol-associated hepatitis trial, plans phase 3 anyway as investors scorch stock (FierceBiotech.com)
Nov-07-23 04:01PM	DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality (PR Newswire)
Oct-19-23 10:44AM	These 2 Strong Buy Penny Stocks Have Massive Upside Potential, Says Oppenheimer (TipRanks) +12.31%
Oct-02-23 03:07PM	3 Promising Biotech Stocks That Will Make Early Investors Rich (InvestorPlace)
Sep-07-23 07:00AM	DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis (PR Newswire)
Aug-31-23 04:30PM	DURECT Corporation Announces Presentations in Upcoming Investor Conferences (PR Newswire)
Aug-14-23 07:55AM	10 Oversold Penny Stocks To Buy (Insider Monkey)
Aug-10-23 07:08AM	Q2 2023 DURECT Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-09-23 05:50PM	Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:43PM	Durect: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update (PR Newswire)
Aug-03-23 04:30PM	DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update (PR Newswire)
Jul-28-23 04:19PM	10 Best Rated Penny Stocks to Buy According to Analysts (Insider Monkey) +8.52%
Jul-20-23 08:00AM	DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire) -33.13%
Jun-07-23 06:00AM	DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis (PR Newswire)
May-11-23 09:55AM	Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet (Zacks)
May-08-23 05:25PM	Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.60%
04:23PM	Durect: Q1 Earnings Snapshot (AP Finance)
04:05PM	DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update (PR Newswire)
May-01-23 07:03PM	DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8 (PR Newswire)
Apr-27-23 05:11PM	DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis (PR Newswire)
Apr-25-23 06:45PM	DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference (PR Newswire)
Apr-10-23 06:00AM	DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis (PR Newswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Mar-21-23 04:30PM	DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board (PR Newswire)
Mar-11-23 07:33AM	DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 08:30AM	DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-08-23 05:53AM	Q4 2022 DURECT Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 05:35PM	Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update (PR Newswire)
Feb-28-23 06:07PM	DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7 (PR Newswire)
Feb-17-23 06:30AM	7 Stocks Under $10 to Buy in February (InvestorPlace)
Feb-03-23 05:17PM	DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants (PR Newswire) -9.38%
Jan-11-23 07:59AM	Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock? (Zacks)

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farfel Gail M	Director	Sep 10 '25	Option Exercise	1.22	5,500	6,710	15,500	Sep 11 06:00 PM
BROWN JAMES E	President & CEO	Sep 09 '25	Option Exercise	1.30	131,923	171,500	415,335	Sep 11 05:52 PM
BROWN JAMES E	President & CEO	Sep 10 '25	Option Exercise	1.30	130,000	169,000	545,335	Sep 11 05:52 PM
Robertson Judith J.	Director	Sep 10 '25	Option Exercise	1.22	5,500	6,710	41,113	Sep 11 05:50 PM
GARCIA PETER S	Director	Sep 09 '25	Option Exercise	1.22	5,500	6,710	12,500	Sep 11 05:48 PM
Maderis Gail J	Director	Sep 09 '25	Option Exercise	1.22	5,500	6,710	5,500	Sep 11 01:14 PM
BROWN JAMES E	President & CEO	Sep 08 '25	Option Exercise	1.30	10,000	13,000	283,412	Sep 10 09:23 PM
JUDITH ROBERTSON	Director	Sep 10 '25	Proposed Sale	1.93	5,500	10,624		Sep 10 04:07 PM
Papp Timothy M.	Chief Financial Officer	Sep 08 '25	Option Exercise	1.30	110,000	143,000	431,659	Sep 09 07:17 PM
ASEN R SCOTT	10% Owner	Aug 22 '25	Buy	1.92	5,917	11,357	2,672,529	Aug 26 03:41 PM
ASEN R SCOTT	10% Owner	Aug 21 '25	Buy	1.90	116,612	221,306	2,666,612	Aug 22 06:10 AM
ASEN R SCOTT	10% Owner	Aug 20 '25	Buy	1.89	87,608	165,360	970,000	Aug 22 06:10 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Durect Corp

Upgrade your FINVIZ experience